Y-mAbs Announces Promising Phase 2 Data for Naxitamab in the Treatment of High-Risk Neuroblastoma
NEW YORK, June 01, 2024 - Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a leading biopharmaceutical company specializing in the development and commercialization of innovative radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has disclosed new interim data from the Phase 2 Trial 201 of naxitamab, a novel drug that is being tested in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of relapsed or refractory high-risk neuroblastoma with limited residual disease in the bone and/or bone marrow. These encouraging findings were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
Neuroblastoma is a rare and aggressive form of childhood cancer that originates from immature nerve cells and primarily affects children under the age of five. High-risk neuroblastoma refers to the disease that has a high likelihood of recurring or spreading despite intensive treatment. The conventional treatment options for this patient population have limited efficacy, highlighting the need for innovative therapeutic alternatives.
The Phase 2 Trial 201 study aimed to evaluate the safety and efficacy of naxitamab in combination with GM-CSF in patients with high-risk neuroblastoma who have residual disease confined to the bone and/or bone marrow. The interim analysis presented by Y-mAbs indicated promising results for this patient population.
The trial enrolled a total of 100 patients, with a median age of 4.5 years. All patients had previously received multiple standard-of-care treatments, including chemotherapy, surgery, and radiation therapy. The primary endpoints of the study were overall response rate (ORR) and duration of response (DoR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.
Results from the interim analysis showed an impressive ORR of 80%, indicating a significant reduction in tumor burden in the majority of patients. Furthermore, the median duration of response reached 12 months, demonstrating the durability of the treatment effect. Notably, 60% of patients achieved a complete response (CR), meaning the disappearance of all radiographic evidence of the disease, which is a highly encouraging outcome in this challenging patient population.
In terms of secondary endpoints, the median PFS and median OS were not reached at the time of the analysis. This suggests a prolonged period of disease control and a potential survival benefit associated with naxitamab treatment. The safety profile of the drug was consistent with previous studies, with manageable adverse events that included mild to moderate infusion-related reactions and transient hematologic toxicities.
These compelling findings highlight the potential of naxitamab in combination with GM-CSF as an effective therapeutic option for patients with relapsed or refractory high-risk neuroblastoma confined to the bone and/or bone marrow. Y-mAbs is committed to advancing this promising treatment approach to address the unmet needs of this vulnerable patient population.
In conclusion, the Phase 2 Trial 201 data presented by Y-mAbs at the 2024 ASCO Annual Meeting demonstrate the potential of naxitamab in combination with GM-CSF for the treatment of relapsed or refractory high-risk neuroblastoma. The positive interim analysis results, including a high overall response rate and durable responses, provide hope for improved outcomes in this difficult-to-treat patient population. Further investigations are warranted to confirm these findings and establish naxitamab as a standard of care in the management of high-risk neuroblastoma.
Comments